At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
Carmustine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Melphalan HCl for Injection (Propylene Glycol-free), Combined With Carmustine, Etoposide, and Cytarabine (BEAM Regimen) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
In Brief
A Phase 2 clinical trial evaluating Carmustine, Etoposide phosphate, and 2 other interventions for Hodgkin Disease and Lymphoma, Non-Hodgkin. Completed, enrolled 50 participants across 1 site.
Detailed Summary
Phase II study is being conducted to confirm the safety and efficacy of high-dose Melphalan HCl for Injection (Propylene Glycol-Free) when included in the BEAM regimen for myeloablative conditioning in lymphoma patients undergoing ASCT
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin Disease, Lymphoma, Non-Hodgkin
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 2013
Enrollment StartMar 2014
Primary CompletionSep 2015
Study CompletionMay 2017
TodayJul 2026
First PostedOct 25, 2013
Enrollment StartMar 19, 2014
Primary CompletionSep 30, 2015
Study CompletionMay 31, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 12.7 years ago
Interventions
Carmustinedrug
Etoposide phosphatedrug
Cytarabinedrug
Melphalan HCl (propylene glycol-free)drug